Odonate Therapeutics (ODT) Stock Analysis
NASDAQHealthcareBiotechnology
What Odonate Therapeutics does
Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.
Key metrics
ETFs linked to ODT
Broad-market and Healthcare sector ETFs an investor holding Odonate Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how ODT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze ODT in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Odonate Therapeutics?
- Odonate Therapeutics trades under the ticker ODT on NASDAQ.
- Which exchange is ODT listed on?
- ODT is listed on NASDAQ.
- What sector does Odonate Therapeutics operate in?
- Odonate Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze ODT in a portfolio?
- PortView shows ODT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.